Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015.

Tina Bech Olesen Ina Trolle Andersen Anne Gulbech Ording Vera Ehrenstein Anouchka SeesaghurCarsten HellebergTrine SilkjærRohini K HernandezDaniela NiepelNiels Abildgaard

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need.

Keyphrases

newly diagnosed
multiple myeloma
end stage renal disease
ejection fraction
peritoneal dialysis
bone mineral density
patient reported outcomes
postmenopausal women
soft tissue
patient reported